氨甲环酸对接受重组血管性血友病因子治疗的1型血管性血友病产后出血的影响
VWD-Woman 是一项3期、开放标签、随机先导试验,纳入20例1型血管性血友病孕妇,比较重组血管性血友病因子联合氨甲环酸与单用重组血管性血友病因子预防产后出血的效果。两组定量失血量、产后出血率、血红蛋白变化及21天PBAC评分均无显著差异,未发生严重不良事件或血栓事件。氨甲环酸联合重组血管性血友病因子可行且安全,但未降低产后出血。
要点
- 两组产后出血率均为30%,定量失血量无显著差异。
- 氨甲环酸联合重组血管性血友病因子可行且安全,未发生严重不良事件或血栓事件。
- 入组孕妇100%存在铁缺乏。
核心结论
- 氨甲环酸联合重组血管性血友病因子在1型血管性血友病中可行且安全,但在这项小型先导研究中与单用重组血管性血友病因子相比未降低产后出血。
- 铁缺乏普遍存在,需要进一步研究以改善血管性血友病产后出血的预防。
研究设计与样本
- VWD-Woman 是一项3期、开放标签、随机先导试验,纳入年龄≥18岁、VWF:RCo<0.50 IU/mL且有出血史的妊娠期血管性血友病女性。
- 共筛查103例,40例符合条件,最终入组20例(每组10例)。
- 参与者分娩时及产后第1天和第2天接受静脉重组血管性血友病因子80 IU/kg,随机联合或不联合氨甲环酸(分娩后3小时内1 g)。
- 主要结局为分娩时定量失血量,次要结局包括21天PBAC评分、血红蛋白变化、输血、子宫切除及安全性。
- 试验注册号NCT04344860。
主要发现
- 平均定量失血量:氨甲环酸联合重组血管性血友病因子组727.0 mL(95%CI 434.5-1019.5)vs 单用重组血管性血友病因子组539.7 mL(95%CI 132.8-946.6),P=0.41。
- 产后出血率两组均为30%。
- 血红蛋白变化:氨甲环酸联合组-1.90 g/dL vs 单用组-1.42 g/dL,P=0.49。
- 21天PBAC评分:氨甲环酸联合组467.1 vs 单用组344.8,P=0.32。
- 按年龄、体重指数、VWF活性或分娩方式分层分析均未显示差异,未发生严重不良事件或血栓事件。
关键数值与推荐
- 入组标准为VWF:RCo<0.50 IU/mL且有出血史。
- 重组血管性血友病因子给药方案为分娩时及产后第1天和第2天静脉80 IU/kg。
- 氨甲环酸给药方案为分娩后3小时内1 g。
临床怎么用
- 作者认为氨甲环酸联合重组血管性血友病因子在1型血管性血友病中可行且安全。
- 作者指出在这项小型先导研究中氨甲环酸联合重组血管性血友病因子与单用重组血管性血友病因子相比未降低产后出血。
- 作者认为需要进一步研究以改善血管性血友病产后出血的预防。
局限性
- 原文指出这是一项小型先导研究。
- 原文结论指出需要进一步研究以改善血管性血友病产后出血的预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Postpartum hemorrhage (PPH) affects up to 44% of women with von Willebrand disease (VWD) despite von Willebrand factor (VWF) replacement. Because tranexamic acid (TXA) reduced PPH-related deaths in the WOMAN trial, we assessed whether TXA combined with rVWF vs rVWF alone prevents PPH in VWD. VWD-Woman, a phase 3, open-label, randomized pilot trial, enrolled pregnant women with VWD, aged ≥18 years (von Willebrand Factor Ristocetin Cofactor activity [VWF:RCo] of <0.50 IU/mL, bleeding history). Participants received IV rVWF 80 IU/kg at delivery and postpartum days 1 and 2, with or without TXA (1 g within 3 hours of delivery). The primary outcome was quantitative blood loss (QBL) at delivery. Secondary outcomes included 21-day pictorial blood assessment chart (PBAC) scores, hemoglobin changes, transfusions, hysterectomy, and safety. Of 103 screened, 40 were eligible, and 20 enrolled (10 per group), 100% were iron-deficient. Mean QBL was similar (TXA + rVWF: 727.0 mL; 95% CI, 434.5-1019.5] vs rVWF: 539.7 mL [95% CI, 132.8-946.6]; P = 0.41), as were rates of PPH (30% in both groups). No differences were observed in hemoglobin change (-1.90 g/dL vs -1.42 g/dL, P = 0.49) or 21-day PBAC score (467.1 vs 344.8, P = 0.32). Stratified analyses showed no differences by age, body mass index, VWF activity, or delivery type. No serious adverse events or thrombosis occurred. TXA plus rVWF is feasible and safe in type 1 VWD, but in this small pilot study, was not associated with a reduction in PPH compared with rVWF alone. Iron deficiency is prevalent. Further studies are needed to improve PPH prevention in VWD. This trial was registered at www.ClinicalTrials.gov as #NCT04344860.
引用
- Machin NC, Brooks MM, Vehec D, et al. Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF. Blood Adv. 2025. PMID: 40902088. doi:10.1182/bloodadvances.2025017046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。